P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL

• Thomas D. Coates,
• Maria Domenica Cappellini,
• Sujit Sheth,
• Kevin H.M. Kuo,
• Antonio Giulio Piga,
• Antonis Kattamis,
• Martina Perin,
• Frederik Lersch,
• Jeevan K. Shetty,
• Yinzhi Lai,
• Wen-Ling Kuo,
• Ali T. Taher

Affiliations

Thomas D. Coates

1 Children’s Hospital Los Angeles, Children’s Center for Cancer and Blood Diseases, Los Angeles, CA, United States

Maria Domenica Cappellini

3 Fondazione IRCCS Ca’ Granda Policlinico Hospital, University of Milan, Milan, Italy

Sujit Sheth

4 Weill Cornell Medicine, Division of Pediatric Hematology/Oncology, New York, NY, United States

Kevin H.M. Kuo

5 University Health Network, Division of Medical Oncology and Hematology, Department of Medicine, Toronto, ON, Canada

Antonio Giulio Piga

7 University of Turin, Turin, Italy

Antonis Kattamis

8 National and Kapodistrian University of Athens, First Department of Pediatrics, Athens, Greece

Martina Perin

9 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Frederik Lersch

9 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Jeevan K. Shetty

9 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Yinzhi Lai

10 Bristol Myers Squibb, Princeton, NJ, United States

Wen-Ling Kuo

10 Bristol Myers Squibb, Princeton, NJ, United States

Ali T. Taher

11 American University of Beirut Medical Center, Department of Internal Medicine, Beirut, Lebanon